Drugs / CLBR001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06913608 | Mar 2026 | idiopathic inflammatory myopathy, systemic lupus erythematosus, systemic sclerosis | Calibr, a division of Scripps Research | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06878248 | Apr 2025 → Apr 2026 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Calibr, a division of Scripps Research | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04488354 | Jan 2021 → Oct 2025 | Burkitt lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma +3 | Calibr, a division of Scripps Research | Completed | No outcome recorded |
| Phase 1 | NCT04450069 | Aug 2020 → May 2024 | Burkitt lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma +3 | Calibr, a division of Scripps Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLBR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06913608 ↗ |
| Modality | Cell therapy | “autologous chimeric antigen receptor T (CAR-T) cell product” NCT04450069 ↗ |
| Route | Other | “Patients will be administered a single infusion of CLBR001 cells” NCT04450069 ↗ |